De Bernardi A, Bezzio C, Puricelli M, Gilardi D, Saibeni S
J Clin Med. 2025; 14(2).
PMID: 39860594
PMC: 11766407.
DOI: 10.3390/jcm14020590.
Fabisiak A, Caban M, Dudek P, Strigac A, Malecka-Wojciesko E, Talar-Wojnarowska R
Therap Adv Gastroenterol. 2025; 18:17562848241309871.
PMID: 39758970
PMC: 11694300.
DOI: 10.1177/17562848241309871.
Jin X, Sun K, Wang L, Shen H, Ma D, Shen T
Therap Adv Gastroenterol. 2025; 18:17562848241307598.
PMID: 39758966
PMC: 11696958.
DOI: 10.1177/17562848241307598.
Solitano V, Ma C, Hanzel J, Panaccione R, Feagan B, Jairath V
Gastroenterol Hepatol (N Y). 2023; 19(5):251-263.
PMID: 37799456
PMC: 10548249.
Berinstein E, Sheehan J, Jacob J, Steiner C, Stidham R, Shannon C
Dig Dis Sci. 2023; 68(6):2604-2623.
PMID: 36807832
PMC: 9942632.
DOI: 10.1007/s10620-023-07837-0.
Update on Immune Checkpoint Inhibitor Enterocolitis.
Kelly-Goss M, Badran Y, Dougan M
Curr Gastroenterol Rep. 2022; 24(12):171-181.
PMID: 36264425
PMC: 9583048.
DOI: 10.1007/s11894-022-00852-7.
Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn's disease: A case report and review of literature.
Au M, Mitrev N, Leong R, Kariyawasam V
World J Clin Cases. 2022; 10(8):2569-2576.
PMID: 35434082
PMC: 8968582.
DOI: 10.12998/wjcc.v10.i8.2569.
Triple therapy with adalimumab, ustekinumab and methotrexate for induction of remission in moderate to severe ileocolonic Crohn's disease with upper gastrointestinal involvement in a biologic-experienced individual.
Yu N, Sarwal D, Ash R, Aslinia F
BMJ Case Rep. 2021; 14(10).
PMID: 34645625
PMC: 8515434.
DOI: 10.1136/bcr-2021-243500.
Tumor Necrosis Factor's Pathway in Crohn's Disease: Potential for Intervention.
Pagnini C, Cominelli F
Int J Mol Sci. 2021; 22(19).
PMID: 34638616
PMC: 8508644.
DOI: 10.3390/ijms221910273.
Efficacy and Safety of Dual Biologic Therapy in Patients With Inflammatory Bowel Disease: A Review of the Literature.
Gold S, Steinlauf A
Gastroenterol Hepatol (N Y). 2021; 17(9):406-414.
PMID: 34602905
PMC: 8475252.
Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature.
Olbjorn C, Rove J, Jahnsen J
Paediatr Drugs. 2020; 22(4):409-416.
PMID: 32378002
PMC: 7383034.
DOI: 10.1007/s40272-020-00396-1.
A Rare Case of New-Onset Ulcerative Colitis following Initiation of Secukinumab.
Achufusi T, Harnee P, Rawlins S
Case Rep Med. 2019; 2019:2975631.
PMID: 31467555
PMC: 6701396.
DOI: 10.1155/2019/2975631.
Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases.
Liefferinckx C, Verstockt B, Gils A, Tops S, van Moerkercke W, Vermeire S
United European Gastroenterol J. 2019; 7(6):750-758.
PMID: 31316779
PMC: 6620879.
DOI: 10.1177/2050640619841538.
Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor.
Pagnini C, Pizarro T, Cominelli F
Front Pharmacol. 2019; 10:671.
PMID: 31316377
PMC: 6611384.
DOI: 10.3389/fphar.2019.00671.
Safety of dual biological therapy in Crohn's disease: a case series of vedolizumab in combination with other biologics.
Mao E, Lewin S, Terdiman J, Beck K
BMJ Open Gastroenterol. 2018; 5(1):e000243.
PMID: 30538822
PMC: 6254738.
DOI: 10.1136/bmjgast-2018-000243.
Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.
Scribano M
World J Gastroenterol. 2018; 24(23):2457-2467.
PMID: 29930467
PMC: 6010939.
DOI: 10.3748/wjg.v24.i23.2457.
The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.
Paramsothy S, Rosenstein A, Mehandru S, Colombel J
Mucosal Immunol. 2018; 11(6):1558-1570.
PMID: 29907872
PMC: 6279599.
DOI: 10.1038/s41385-018-0050-3.
A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis.
Ehrlich D, Jamaluddin N, Pisegna J, Padua D
Case Rep Gastrointest Med. 2018; 2018:9679287.
PMID: 29666723
PMC: 5832071.
DOI: 10.1155/2018/9679287.
Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease.
Liu E, Loomes D
Case Rep Med. 2017; 2017:5264216.
PMID: 29250117
PMC: 5698793.
DOI: 10.1155/2017/5264216.
Long-term Combination Therapy with Anti-TNF plus Vedolizumab Induces and Maintains Remission in Therapy-refractory Ulcerative Colitis.
Fischer S, Rath T, Geppert C, Manger B, Schett G, Neurath M
Am J Gastroenterol. 2017; 112(10):1621-1623.
PMID: 28978957
DOI: 10.1038/ajg.2017.242.
